TARGECIDAL®

Pioneering Precision in Microbiome Health through Targeted Bactericidal Therapy

Discover Our Innovation

Our Mission & Vision

Our Mission

- To reshape microbiome health through targeted bactericidal technology, specifically phage lysins.

- Ending dental caries, combating antimicrobial resistance.

- We believe in Medicine for the People, Profit Follows—advancing scientific innovation to serve public health and benefit humanity.

Our Vision

- To become the global leader in phage lysin technology, redefining microbial therapeutics through targeted bactericidal innovation.

- Rooted in China, reaching the world, we aim to build a multi-indication, multi-application product platform centered on precision bacterial control and microbiome reconstruction.

Human Microbiome Illustration

Core Values

- Diligence and Pragmatism, Inspiration and Integrity."勤奋求实 励志明德"

- Work with great people, Tap dance to work, and build a life of purpose

- Build a community of happiness: empowering scientists to benefit society, creating value for employees, and delivering sustainable returns to investors

Revolutionizing Dental Caries Prevention

The Global Challenge

3.5B
People worldwide suffering from oral diseases
3/4
Live in low and middle-income countries
2+B
People with untreated dental caries in permanent teeth globally
$387B
Global direct medical expenditure for oral diseases in 2019
Oral Health Connection

Our Revolutionary Approach

Targeted
Effective solely against cariogenic bacteria like S. mutans, A. naeslundii, and S. sobrinus, with no impact on commensal bacteria
84%
Killing rate of S. mutans in 1 minute
Day 21
S. mutans abundance remains low, even after treatment was discontinued on day 6
93.1%
Biofilm elimination rate
Oral Bacteria Illustration

Preclinical Data Highlights

Our lead candidate, LysP53, has demonstrated exceptional efficacy and an outstanding safety profile in rigorous preclinical studies:

  • Targeted Efficacy: LysP53 exhibits remarkable specificity, proving effective exclusively against cariogenic bacteria, including Streptococcus mutans, Actinomyces naeslundii, and Streptococcus sobrinus.
  • Potent Bactericidal Activity: A mere 4 µM concentration achieves over 84% killing of S. mutans within just one minute of exposure.
  • Outstanding Safety Profile: Cytotoxicity tests revealed no significant difference in cell viability compared to control groups, demonstrating excellent biocompatibility.

Connect with TARGECIDAL®

We invite you to connect with us to learn more about our groundbreaking work, explore potential collaborations, or inquire about investment opportunities.

Our Headquarters

Building F295, No.2, Lane 158, Gangye Road
Xiaokunshan Town, Songjiang District
Shanghai, China 201614

General Inquiries

targecidal@163.com

About TARGECIDAL®

A Legacy of Expertise and Innovation

TARGECIDAL® is a dynamic biotechnology startup founded by a team of seasoned experts with over a decade of invaluable experience in the pharmaceutical and biotechnology sectors. Our genesis is rooted in a profound understanding of critical clinical unmet needs and a passion for leveraging advanced microbial control technologies. We are singularly focused on developing innovative and highly effective bactericidal solutions for a wide spectrum of microbiome-related diseases. Our core strategy revolves around harnessing the power of phage lysins, a revolutionary class of antimicrobials, to precisely target and mitigate urgent global health challenges such as the escalating crisis of antimicrobial resistance and the pervasive burden of dental caries. At TARGECIDAL®, we are not just developing products; we are forging a new paradigm in precision medicine, committed to delivering transformative health outcomes for patients worldwide.